Abstracts
Showing 14 abstracts.
Citation
T Ruel, E Acosta, RP Singh, C Alvero, K George, S Popson, C Vavro, R Hazra, A Wiznia. Dolutegravir pharmacokinetics, safety and efficacy in HIV+ children 2 to 6 years old. Presented at: CROI 2017; 2017 Feb 16.Conference
CROI 2017
Study
P1093
Citation
CL Boyce, RA Smith, R Nixon, MD Bishop, SM Styrchak, K Knowles, S Brummel, TD Ruel, A Wiznia, S Lockman, L Chinula, PK Drain, GS Gottlieb, LM Frenkel. Genotypic and Phenotypic Dolutegravir Resistance in Pregnant Women and Children Living with HIV-1. Presented at: International Workshop on HIV Drug Resistance and Treatment Strategies; 2023 Sep 20.Conference
International Workshop on HIV Drug Resistance and Treatment Strategies
Study
IMPAACT 2010, P1093
Citation
Pharmacokinetics, Safety, and Efficacy of Dolutegravir (DTG; S/GSK1349572) in HIV-1 Infected Adolescents: Preliminary analysis from IMPAACT 1093. Presented at: XIX International AIDS Conference.Conference
XIX International AIDS Conference
Study
P1093
Citation
D Burger, E Acosta, N van Ewijk, C Taylor, P Bollen, T Ruane, A Colbers, A Turkova, R Di Francesco, G Morse, R Browne. PROFICIENCY TESTING SUPPORTS COMBINED ANALYSIS OF DOLUTEGRAVIR PHARMACOKINETIC DATA. Presented at: CROI 2019.Conference
CROI 2019
Study
P1093